ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) CFO Stephen Carey sold 2,850 shares of the stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $72.87, for a total value of $207,679.50. Following the completion of the transaction, the chief financial officer owned 166,143 shares in the company, valued at approximately $12,106,840.41. The trade was a 1.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ANI Pharmaceuticals Stock Down 1.6%
NASDAQ:ANIP traded down $1.16 during midday trading on Friday, hitting $72.00. 286,882 shares of the company were exchanged, compared to its average volume of 378,435. ANI Pharmaceuticals, Inc. has a fifty-two week low of $69.58 and a fifty-two week high of $95.57. The company has a market capitalization of $1.65 billion, a PE ratio of 15.52, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The company has a fifty day simple moving average of $73.06 and a 200 day simple moving average of $77.74.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same period last year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several brokerages recently commented on ANIP. Canaccord Genuity Group dropped their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Guggenheim decreased their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Oppenheimer initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 price objective on the stock. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $99.60.
View Our Latest Stock Report on ANI Pharmaceuticals
Hedge Funds Weigh In On ANI Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE acquired a new position in ANI Pharmaceuticals during the second quarter worth $15,154,000. NFJ Investment Group LLC bought a new position in ANI Pharmaceuticals during the second quarter valued at about $2,766,000. Walleye Capital LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $8,784,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $1,449,000. Finally, Jupiter Topco LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $6,597,000. Institutional investors own 76.05% of the company’s stock.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.
ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
